首页> 外国专利> use of a compound with ep4 antagonistic activity or a pharmaceutically acceptable salt thereof, use of a compound of formula (i), (ii), (iii), (iv), (va) or (vb) or a pharmaceutically acceptable salt thereof, pharmaceutical composition for treating cartilage disease, method for treating cartilage disease in an animal subject, including a mammalian subject and compound of formula (i), (ii), (iii), (iv), ( va) or (vb) or a pharmaceutically acceptable salt thereof.

use of a compound with ep4 antagonistic activity or a pharmaceutically acceptable salt thereof, use of a compound of formula (i), (ii), (iii), (iv), (va) or (vb) or a pharmaceutically acceptable salt thereof, pharmaceutical composition for treating cartilage disease, method for treating cartilage disease in an animal subject, including a mammalian subject and compound of formula (i), (ii), (iii), (iv), ( va) or (vb) or a pharmaceutically acceptable salt thereof.

机译：具有ep4拮抗活性的化合物或其药学上可接受的盐的用途，式（i），（ii），（iii），（iv），（va）或（vb）化合物或其药学上可接受的盐的用途，用于治疗软骨疾病的药物组合物，用于治疗动物受试者（包括哺乳动物受试者）和式（i），（ii），（iii），（iv），（va）或（vb）的化合物的软骨疾病的方法或其药学上可接受的盐。

页面导航

摘要
著录项
相似文献

摘要

This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a pharmaceutical composition for the treatment of cartilage disease which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of cartilage disease in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.

机译：本发明涉及具有EP4拮抗活性的化合物，或具有EP4受体拮抗活性的药学上可接受的盐，其可用于治疗软骨疾病。本发明还涉及具有EP4受体拮抗活性的式（I），（II），（III），（IV），（Va）或（Vb）的化合物或其药学上可接受的盐，其可用于软骨疾病的治疗。本发明还涉及用于治疗软骨疾病的药物组合物，其包含治疗有效量的式（I），（II），（III），（IV），（Va）或（Vb）的化合物，或其药学上可接受的盐。本发明还涉及一种在包括哺乳动物受试者的动物受试者中治疗软骨疾病的方法，该方法包括向包括哺乳动物受试者的动物受试者施用式（I），（II），（III）的化合物，（IV），（Va）或（Vb）或其药学上可接受的盐。

著录项

公开/公告号BR112015023663A2

专利类型
公开/公告日2017-07-18

原文格式PDF
申请/专利权人 ASKAT INC.;
展开▼

申请/专利号BR20151123663
发明设计人 TAKAKO OKUMURA;
展开▼

申请日2014-03-19
分类号A61K31/44;A61K31/341;A61K31/381;A61K31/437;A61K45;A61P19/02;C07D213/89;C07D307/64;C07D333/38;C07D471/04;
国家 BR
入库时间 2022-08-21 13:40:03

相似文献

专利
外文文献